European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · 2009
An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fernández-Jaén Alberto, Fernández-Mayoralas Daniel Martín, Muñoz-Jareño Nuria, Calleja-Pérez Beatriz
Аннотация
OBJECTIVES: To evaluate the usefulness of levetiracetam (LEV) for the treatment of tics in patients with Tourette syndrome (TS) by means of a prospective, open-label, 12-week study.
MATERIAL AND METHODS: Twenty-nine patients with TS who received LEV to control their tics were admitted to the study. The authors recorded the following variables: initial status (Yale Global Tic Severity Scale - YGTSS - and the scale of Modified Clinical Global Impression -MCGI), the clinical status at 3 months using the same scales, and clinical/medical impression of improvement.
RESULTS: The mean age of the patients studied was 12 years; 25 males (86%) and 4 females (14%). Participants received 800-2000 mg/day of LEV. Of the 29 patients, 21 children (72%) improved according to YGTSS and MCGI scores. Mean YGTSS Total Tic Score at baseline and after treatment with LEV were 67 and 44, respectively. The statistical analysis confirmed a significant improvement with a p-value of <0.001 on the YGTSS and MCGI. In 3 cases, treatment was suspended due to adverse effects.
CONCLUSIONS: Treatment with LEV can constitute a treatment option for tics in patients with TS. Double-blind trials of longer duration are needed in larger samples in order to establish both the benefit, as well as what patients are eligible for treatment.
MATERIAL AND METHODS: Twenty-nine patients with TS who received LEV to control their tics were admitted to the study. The authors recorded the following variables: initial status (Yale Global Tic Severity Scale - YGTSS - and the scale of Modified Clinical Global Impression -MCGI), the clinical status at 3 months using the same scales, and clinical/medical impression of improvement.
RESULTS: The mean age of the patients studied was 12 years; 25 males (86%) and 4 females (14%). Participants received 800-2000 mg/day of LEV. Of the 29 patients, 21 children (72%) improved according to YGTSS and MCGI scores. Mean YGTSS Total Tic Score at baseline and after treatment with LEV were 67 and 44, respectively. The statistical analysis confirmed a significant improvement with a p-value of <0.001 on the YGTSS and MCGI. In 3 cases, treatment was suspended due to adverse effects.
CONCLUSIONS: Treatment with LEV can constitute a treatment option for tics in patients with TS. Double-blind trials of longer duration are needed in larger samples in order to establish both the benefit, as well as what patients are eligible for treatment.